Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Foghorn Therapeutics
Deal Size : $380.0 million
Deal Type : Collaboration
Details : The collaboration includes co-development and co-commercialization agreement for Foghorn’s selective BRM oncology program and undisclosed oncology target. The collaboration includes three additional discovery programs using Foghorn’s proprietary Gene...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $300.0 million
December 13, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Foghorn Therapeutics
Deal Size : $380.0 million
Deal Type : Collaboration
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : First-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising antitumour activity and safety in various RET fusion-positive advanced solid tumours. Safety consistent with known profile of Retevmo.
Brand Name : Retevmo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2021
Lead Product(s) : Selpercatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Loxo-305
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305
Details : In the 121 efficacy-evaluable BTK-pretreated patients, the ORR was 62%. This deepening of response over time is consistent with other BTK inhibitors and suggests the overall efficacy profile of LOXO-305 will continue to strengthen with additional follow-...
Brand Name : LOXO-305
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2020
Lead Product(s) : Loxo-305
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Loxo-305,Venetoclax,Rituximab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LOXO-305 oral presentations will provide updated data from the ongoing Phase 1/2 BRUIN clinical trial in previously treated chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, and other non-Ho...
Brand Name : LOXO-305
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 05, 2020
Lead Product(s) : Loxo-305,Venetoclax,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
